2022
Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection
Le LT, Price RW, Gisslén M, Zetterberg H, Emu B, Fabre R, Christian P, Andersen S, Spudich S, Vassallo M. Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection. HIV Medicine 2022, 24: 442-452. PMID: 36134890, DOI: 10.1111/hiv.13411.Peer-Reviewed Original ResearchConceptsCD4/CD8 ratioPrimary HIV infectionCD8 ratioImmune activationHIV infectionNeuronal injuryAntiretroviral treatmentNeurocognitive performanceMean CD4/CD8 ratioCSF neurofilament light chainART-naïve participantsEarly HIV infectionCerebrospinal fluid markersNeurofilament light chainNeuropsychological testing performancePsychomotor speed performancePHI participantsStudy cohortCSF markersChronic infectionBrain injuryRetrospective analysisFluid markersInfectionInjury
2021
Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349)
Mazurek M, Yuen M, Cahn B, Rosen M, Gobeske K, Gilmore E, Hwang D, Kaddouh F, Kim J, Falcone G, Petersen N, Siner J, Spudich S, Sze G, Kimberly W, Sheth K. Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1349.Peer-Reviewed Original Research
2020
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients
Sheth KN, Mazurek MH, Yuen MM, Cahn BA, Shah JT, Ward A, Kim JA, Gilmore EJ, Falcone GJ, Petersen N, Gobeske KT, Kaddouh F, Hwang DY, Schindler J, Sansing L, Matouk C, Rothberg J, Sze G, Siner J, Rosen MS, Spudich S, Kimberly WT. Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. JAMA Neurology 2020, 78: 41-47. PMID: 32897296, PMCID: PMC7489395, DOI: 10.1001/jamaneurol.2020.3263.Peer-Reviewed Original ResearchIntensive care unit roomsIntensive care settingBrain injuryCare settingsIll patientsNeurological injuryT2 fluid-attenuated inversion recoveryCOVID-19Intensive care unit admissionSingle-center cohort studyIntensive care unit settingUnit roomsYale-New Haven HospitalNasopharyngeal swab resultsCare unit admissionSingle-center seriesBrain imaging findingsIntensive care unitFluid-attenuated inversion recoveryDiffusion-weighted imaging sequencesTraumatic brain injuryClinical care settingsNew Haven HospitalMagnetic resonance imagingConventional magnetic resonance imaging (MRI) system
2011
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study
Ho EL, Spudich SS, Lee E, Fuchs D, Sinclair E, Price RW. Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Research And Therapy 2011, 8: 17. PMID: 21569420, PMCID: PMC3117676, DOI: 10.1186/1742-6405-8-17.Peer-Reviewed Original ResearchCerebrospinal fluidHIV infectionImmune activationPilot studyCSF white blood cell countBlood HIV-1 RNAChronic untreated HIV infectionUntreated HIV-1 infectionWhite blood cell countCell surface activation markersCNS HIV infectionUntreated HIV infectionHIV-1 infectionHIV-1 RNABlood cell countBlood T lymphocytesConclusionsThis pilot studyBlood neopterinCSF CCL2Adjuvant therapyAntiretroviral therapyViremic subjectsActivation markersBlood biomarkersBrain injury
2008
Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection
Price RW, Spudich S. Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection. The Journal Of Infectious Diseases 2008, 197: s294-s306. PMID: 18447615, PMCID: PMC2628635, DOI: 10.1086/533419.Peer-Reviewed Original ResearchConceptsCNS HIV-1 infectionAntiretroviral therapyHIV-1 infectionType 1 infectionCerebrospinal fluidHuman immunodeficiency virus type 1 (HIV-1) infectionSystemic infectionHIV Type 1 InfectionImmunodeficiency syndrome dementia complexVirus type 1 infectionUntreated systemic infectionCombination antiretroviral therapyCNS opportunistic infectionsMinority of patientsEarly treatment interventionLocal inflammatory reactionPrimary viremiaNeurological progressionOpportunistic infectionsDementia complexAsymptomatic infectionSilent infectionBrain injuryInflammatory reactionHIV-1
2006
Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers
Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. Journal Of Neuroimmune Pharmacology 2006, 2: 112-119. PMID: 18040834, DOI: 10.1007/s11481-006-9035-1.Peer-Reviewed Original ResearchConceptsCNS HIV infectionAIDS dementia complexHIV infectionBrain injuryTreatment targetsCentral nervous system infectionNeurodegenerative diseasesSystemic HIV infectionComorbidities of patientsNervous system infectionAdjuvant treatment approachesCerebrospinal fluid markersRational trial designIntrathecal immunoactivationSystem infectionDementia complexAvailable treatmentsClinical trialsFluid markersTrial designTreatment approachesClinical practiceExperimental therapeuticsPatientsInfection